Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3
- PMID: 17984976
- DOI: 10.1038/sj.mt.6300341
Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3
Abstract
Therapies based on enhancing the numbers and/or function of T regulatory cells (Tregs) represent one of the most promising approaches to restoring tolerance in many immune-mediated diseases. Several groups have investigated whether human Tregs suitable for cellular therapy can be obtained by in vitro expansion, in vitro conversion of conventional T cells into Tregs, or gene transfer of the FOXP3 transcription factor. To date, however, none of these approaches has resulted in a homogeneous and stable population of cells that is as potently suppressive as ex vivo Tregs. We developed a lentivirus-based strategy to ectopically express high levels of FOXP3 that do not fluctuate with the state of T-cell activation. This method consistently results in the development of suppressive cells that are as potent as Tregs and can be propagated as a homogeneous population. Moreover, using this system, both naïve and memory CD4(+) T cells can be efficiently converted into Tregs. To date, this is the most efficient and reliable protocol for generating large numbers of suppressive CD4(+) Tregs, which can be used for further biological study and developed for antigen-specific cellular therapy applications.
Similar articles
-
The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs.J Clin Invest. 2005 Nov;115(11):3276-84. doi: 10.1172/JCI24685. Epub 2005 Oct 6. J Clin Invest. 2005. PMID: 16211090 Free PMC article.
-
Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.J Immunol. 2010 Jul 1;185(1):174-82. doi: 10.4049/jimmunol.0903548. Epub 2010 Jun 4. J Immunol. 2010. PMID: 20525892 Free PMC article.
-
Cutting edge: CD4-independent development of functional FoxP3+ regulatory T cells.J Immunol. 2009 Oct 1;183(7):4182-6. doi: 10.4049/jimmunol.0901678. J Immunol. 2009. PMID: 19767568
-
Epigenetic mechanisms of regulation of Foxp3 expression.Blood. 2009 Oct 29;114(18):3727-35. doi: 10.1182/blood-2009-05-219584. Epub 2009 Jul 29. Blood. 2009. PMID: 19641188 Free PMC article. Review.
-
Early Growth Response Gene 2-Expressing CD4+LAG3+ Regulatory T Cells: The Therapeutic Potential for Treating Autoimmune Diseases.Front Immunol. 2018 Feb 26;9:340. doi: 10.3389/fimmu.2018.00340. eCollection 2018. Front Immunol. 2018. PMID: 29535721 Free PMC article. Review.
Cited by
-
Epigenetically mediated pathogenic effects of phenanthrene on regulatory T cells.J Toxicol. 2013;2013:967029. doi: 10.1155/2013/967029. Epub 2013 Mar 7. J Toxicol. 2013. PMID: 23533402 Free PMC article.
-
Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance.Cancer Microenviron. 2013 Aug;6(2):147-57. doi: 10.1007/s12307-012-0122-y. Epub 2012 Oct 27. Cancer Microenviron. 2013. PMID: 23104434 Free PMC article.
-
Ectopic FOXP3 Expression in Combination with TGF-β1 and IL-2 Stimulation Generates Limited Suppressive Function in Human Primary Activated Thymocytes Ex Vivo.Biomedicines. 2021 Apr 23;9(5):461. doi: 10.3390/biomedicines9050461. Biomedicines. 2021. PMID: 33922629 Free PMC article.
-
Perspectives on Regulatory T Cell Therapies.Transfus Med Hemother. 2009;36(5):302-308. doi: 10.1159/000235929. Epub 2009 Sep 10. Transfus Med Hemother. 2009. PMID: 21076548 Free PMC article.
-
Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment.Exp Mol Med. 2023 Sep;55(9):1996-2004. doi: 10.1038/s12276-023-01080-3. Epub 2023 Sep 1. Exp Mol Med. 2023. PMID: 37653036 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials